-
REAL WORLD IMPACT OF LONG ACTING INJECTABLE ANTIPSYCHOTICS ON HEALTHCARE UTILIZATION AND COSTS IN PATIENTS WITH PSYCHOTIC DISORDERS AND INTELLECTUAL DISABILITY IN PORTUGAL
Aug 11, 2026, 17:16 PM -
INSIGHTS FROM A NATIONAL CANCER REGISTRY: CLINICAL CHARACTERISTICS AND TREATMENT PATHWAYS OF METASTATIC BREAST CANCER PATIENTS IN GERMANY - A RETROSPECTIVE ANALYSIS OF ZFKD DATA
Aug 11, 2026, 17:16 PM -
CLINICAL AND ECONOMICAL BURDEN OF CHRONIC SEDATIVE-HYPNOTIC USE FOR INSOMNIA DISORDER: A NATIONWIDE FRENCH CLAIMS DATABASE STUDY
Aug 11, 2026, 17:16 PM -
INDOLENT SYSTEMIC MASTOCYTOSIS IN FRANCE: A FIRST ESTIMATION OF THE ANNUAL MEDICAL AND SOCIOECONOMIC BURDEN
Aug 11, 2026, 17:16 PM -
ESTIMATING THE ECONOMIC BURDEN OF PRE-TRANSPLANT HEMODIALYSIS FOR KIDNEY TRANSPLANT RECIPIENTS IN BRAZIL: INSIGHTS FROM REAL-WORLD DATA
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF SINGLE INHALER BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMARATE DIHYDRATE VERSUS DUAL THERAPY ICS/LABA IN UNCONTROLLED ASTHMA: A UK PERSPECTIVE
Aug 11, 2026, 17:16 PM -
REAL-WORLD EVIDENCE TO ASSESS THE FEASIBILITY OF LOW-DOSE CT LUNG CANCER SCREENING IN THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS)
Aug 11, 2026, 17:16 PM -
CLINICAL PRESENTATION, DIAGNOSTIC UTILIZATION, AND CLINICAL BURDEN IN BING-NEEL SYNDROME: A SYSTEMATIC REVIEW OF PUBLISHED CASE REPORTS
Aug 11, 2026, 17:16 PM -
ECONOMIC MODEL ARCHITECTURE IN NICE EVALUATIONS FOR ULTRA-RARE NON-ONCOLOGY CONDITIONS: A COMPARATIVE ANALYSIS OF STRUCTURAL CHOICES AND CLINICAL TRIAL ENDPOINT USE ACROSS THE STA AND HST PATHWAYS
Aug 11, 2026, 17:16 PM -
CONTRAST-ENHANCED MAMMOGRAPHY (CEM)
Aug 11, 2026, 17:16 PM -
PAVE-MA: A STANDARDIZED, LOCALLY SOURCED PROTOCOL FOR AREA-BY-AREA ECONOMIC EVALUATION OF PREVENTION IN MOROCCO
Aug 11, 2026, 17:16 PM -
IMPACT OF COMPARATOR SELECTION BASED ON SEQUENTIAL ANALYSIS ON COST-EFFECTIVENESS CONCLUSIONS IN CDA-AMC REIMBURSEMENT RECOMMENDATIONS
Aug 11, 2026, 17:16 PM -
COMPARATIVE VALIDATION OF SURVIVAL EXTRAPOLATION USING PARAMETRIC MODELS FOR HEALTH ECONOMIC EVALUATIONS
Aug 11, 2026, 17:16 PM -
WHAT THE FIRST COMPLETED EU JOINT CLINICAL ASSESSMENT DOES NOT TELL US: A STRUCTURED ANALYSIS OF THE TOVORAFENIB JCA AND REMAINING METHODOLOGICAL UNCERTAINTIES
Aug 11, 2026, 17:16 PM -
VALUE SET PLAUSIBLE? EVIDENCE FROM RECENT FRENCH HTA APPRAISALS
Aug 11, 2026, 17:16 PM -
TOOLS FOR ASSESSING RISK OF BIAS IN REAL-WORLD EVIDENCE: A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
TOTAL COST OF CARE ANALYSIS OF FIRST-LINE IMMUNO-ONCOLOGY THERAPIES FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A COLOMBIAN PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
COST-UTILITY OF ENOBOSARM VERSUS RESISTANCE EXERCISE TRAINING FOR SARCOPENIA IN US COMMUNITY DWELLING OLDER ADULTS. A DECISION ANALYTIC MODEL
Aug 11, 2026, 17:16 PM -
IDENTIFICATION AND VALIDATION OF OUTCOMES IMPORTANT TO BOTH PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND SPECIALIST CLINICIANS: A THREE-ROUND DELPHI METHODOLOGY STUDY
Aug 11, 2026, 17:16 PM -
MAXIMUM COST-EFFECTIVE PRICE OF SERPLULIMAB FOR FIRST-LINE EXTENSIVE-STAGE SMALL-CELL LUNG CANCER: A THRESHOLD ANALYSIS FOR THE PERUVIAN PRIVATE HEALTH SYSTEM
Aug 11, 2026, 17:16 PM
